OKOMERA is seeking a highly-motivated microfluidics engineer to develop automated microfluidic droplet solutions for OKOMERA’s clients in 2022. Her/his main missions will be to develop, to optimize, and to make robust automated microfluidic protocols (droplet production, injection, multiplexed conditions).The candidate will perform experiments, write and optimize code. She/he will work in the microfluidics team, under the supervision of the CTO, and will closely collaborate with other OKOMERA members, notably with the bio-application team. Details of missions will vary depending on the level of expertise ofthe recruited profile.
Education : Engineer degree with 2+ years of experience or PhDlevel in Biophysics/Physics/Microfluidics
Proven record (strong laboratory experience) of greatexperimental and practical skills, as well as innovative problemsolving
Good programming skills (Python, C++… )
Good understanding of fluid mechanics at the microscale
Great organization and reporting skills
Ability to work in English within an international team
Ideal candidates may have
Wet-lab experience in biotechnology/biology
Experience in droplet microfluidics and microfabrication would be a real plus
Experience in mammalian cell culture
Experience in prototyping (3D printing, electronics, industrial design)
Contract : CDI
Starting Date : from February 2022
Salary : based on experience
Education Level : PhD level or Engineering degree with 2+ years of industrial experience
Location : Paris, Brain Institute (ICM), Hôpital Pitié-Salpêtrière
About Okomera and Microfluidics for clinical oncology
OKOMERA is a newly created start-up (2020) spun out from Ecole Polytechnique and Institut Pasteur, whose key mission is to help selecting the best treatment for each cancer patient. OKOMERA is currently codeveloping functional ex vivo assays with our clients, key opinion leaders leading research inprecision cancer medicine.
OKOMERA clients currently use our 3D cell culture microfluidic technology  to cultivate primary patient cells from tumor biopsies, and/or cell lines, to assess cell functionalities(drug sensitivity, morphology, migration). OKOMERA’s droplet array technology enables to automate the formation of complex 3D cell cultures (micro-tumors with co-cultures, hydrogels), and to test tens to hundreds of individual conditions on a single chip . OKOMERA prides itself on supplying easy-to-use products (fluidic machine, chips and software) built for non-experts who wish to automate high-throughput 3D sample testing.
OKOMERA was awarded the national iLAB prize from BPI France in 2019, the COMET program from WILCO, iscurrently incubated at Hôpital Pitié Salpêtrière in Paris and recently finalized its initial funding round. We are currently a team of 7, and are actively hiring to grow and deliver our alpha solution to our first clients in early 2022.
1- Sart, R. F.-X. Tomasi, G. Amselem, and C. N. Baroud, “Multiscale cytometry and regulation of 3D cellcultures on a chip,” Nat. Commun., vol. 8, p. 469, 2017.
2- F. X. Tomasi, S. Sart, T. Champetier, and C. N. Baroud, “Individual Control and Quantification of 3DSpheroids in a High-Density Microfluidic Droplet Array,” Cell Rep., vol. 31, no. 8, 2020.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!